Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23,282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial.
Lu H, Zhang G, Mao J, Chen X, Zhan Y, Lin L, Zhang T, Tang Y, Lin F, Zhu F, Lin Y, Zeng Y, Zhang K, Yuan W, Liang Z, Sun R, Huo L, Hu P, Lin Y, Zhuang X, Wei Z, Chen X, Yan W, Yan X, Mu L, Lin Z, Tu X, Tan H, Huang F, Hu Z, Li H, Li G, Fu H, Yang Z, Chen X, Wang FS, Zhong N. Lu H, et al. EClinicalMedicine. 2024 Apr 10;71:102582. doi: 10.1016/j.eclinm.2024.102582. eCollection 2024 May. EClinicalMedicine. 2024. PMID: 38618202 Free PMC article.
Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international multicenter clinical trial.
Zhan YQ, Chen RF, Zheng QS, Li XW, Liu YN, Mootsikapun P, Chayakulkeeree M, Arttawejkul P, Lan TTN, Liu GG, Lu HZ, Liu QQ, Zhong NS, Yang ZF, Zheng JP. Zhan YQ, et al. J Thorac Dis. 2023 May 30;15(5):2859-2872. doi: 10.21037/jtd-23-281. Epub 2023 Apr 23. J Thorac Dis. 2023. PMID: 37324081 Free PMC article.
Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial.
Wang F, Xiao W, Tang Y, Cao M, Shu D, Asakawa T, Xu Y, Jiang X, Zhang L, Wang W, Tang J, Huang Y, Yang Y, Yang Y, Tang R, Shen J, Lu H. Wang F, et al. Among authors: lu h. Lancet Reg Health West Pac. 2023 Jul 11;38:100835. doi: 10.1016/j.lanwpc.2023.100835. eCollection 2023 Sep. Lancet Reg Health West Pac. 2023. PMID: 37484496 Free PMC article.
Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019: an international, multicenter, double-blind, randomized controlled trial.
Zheng JP, Ling Y, Jiang LS, Mootsikapun P, Lu HZ, Chayakulkeeree M, Zhang LX, Arttawejkul P, Hu FY, Truong TNL, Perez RA, Gu X, Sun HM, Jiang JJ, Liu RJ, Ding Z, Zhan YQ, Yang ZF, Guan WJ, Zhong NS. Zheng JP, et al. Virol J. 2023 Nov 28;20(1):277. doi: 10.1186/s12985-023-02144-6. Virol J. 2023. PMID: 38017515 Free PMC article. Clinical Trial.
Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial.
Zhan Y, Lin Z, Liang J, Sun R, Li Y, Lin B, Ge F, Lin L, Lu H, Su L, Xiang T, Pan H, Huang C, Deng Y, Wang F, Xu R, Chen D, Zhang P, Tong J, Wang X, Meng Q, Zheng Z, Ou S, Guo X, Yao H, Yu T, Li W, Zhang Y, Jiang M, Fang Z, Song Y, Chen R, Luo J, Kang C, Liang S, Li H; other Collaborative Institutes; Zheng J, Zhong N, Yang Z. Zhan Y, et al. Among authors: lu h. EClinicalMedicine. 2023 Dec 14;67:102359. doi: 10.1016/j.eclinm.2023.102359. eCollection 2024 Jan. EClinicalMedicine. 2023. PMID: 38188690 Free PMC article.
Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with Covid-19.
Jiang R, Han B, Xu W, Zhang X, Peng C, Dang Q, Sun W, Lin L, Lin Y, Fan L, Lv D, Shao L, Chen Y, Qiu Y, Han L, Kong W, Li G, Wang K, Peng J, Lin B, Tong Z, Lu X, Wang L, Gao F, Feng J, Li Y, Ma X, Wang J, Wang S, Shen W, Wang C, Yan K, Lin Z, Jin C, Mao L, Liu J, Kushnareva Y, Kotoi O, Zhu Z, Royal M, Brunswick M, Ji H, Xu X, Lu H. Jiang R, et al. Among authors: lu x, lu h. NEJM Evid. 2024 Jun;3(6):EVIDoa2400026. doi: 10.1056/EVIDoa2400026. Epub 2024 May 28. NEJM Evid. 2024. PMID: 38804790 Clinical Trial.
Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial.
Lu CL, Yang LQ, Jin XY, Friedemann T, Li YF, Liu XH, Chen XY, Zou XY, Zhang BR, Wang FX, Lin YL, Tang YM, Cao ML, Jiang YL, Gao YF, Liu K, Tao ZG, Robinson N, Schröder S, Liu JP, Lu HZ. Lu CL, et al. Front Pharmacol. 2024 May 27;15:1383831. doi: 10.3389/fphar.2024.1383831. eCollection 2024. Front Pharmacol. 2024. PMID: 38863976 Free PMC article.
Characteristics of SARS-CoV-2 Delta variant-infected individuals with intermittently positive retest viral RNA after discharge.
Li L, Tang J, Xie Z, Gan Q, Tang G, Hu Z, Zeng H, Shi J, Li J, Li Y, Ke C, Kang M, Liang D, Lu H, Tong Y, Deng X, Liu J, Lu H, Wang F, Hu F, Li F, Zhong N, Tang X. Li L, et al. Among authors: lu h. Natl Sci Rev. 2022 Jul 26;9(10):nwac141. doi: 10.1093/nsr/nwac141. eCollection 2022 Oct. Natl Sci Rev. 2022. PMID: 36325114 Free PMC article. No abstract available.
23,282 results
You have reached the last available page of results. Please see the User Guide for more information.